Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023
Journal of Viral Hepatitis · 2026-08 · 33 (8)
DOI: 10.1111/jvh.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 15.07.2026. Verfasst von Maito Suoh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Robert W. Storr Bequest to the Sydney Medical Foundation, National Health and Medical Research Council of Australia, Cancer Institute, NSW.
Abstract (Originalsprache)
Interferon‐free direct‐acting antivirals (DAAs), which are highly effective in eliminating hepatitis C virus (HCV), became available in Japan in 2014. This study aimed to estimate the nationwide socioeconomic outcomes of DAA therapy in Japan using publicly available records, including data from the hepatitis subsidy program and universal healthcare claims between fiscal years 2014 and 2023. Based on the standard dose of each DAA regimen, approximately 300,000 people were estimated to have been treated with DAA therapy by 2023, with a cumulative drug cost of at least 1.23 trillion Japanese yen (10.8 billion United States dollars). The main indication for DAA therapy was the initial treatment of chronic HCV infection without cirrhosis. The estimated cost and number of treated people peaked in 2015, followed by a declining trend. For most DAA regimens, annual prescriptions were the greatest in the same or the following year of approval. Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. The age of people treated with DAA therapy shifted towards younger people during the survey period, particularly in males. While the estimated prevalence of people treated with DAA therapy was higher in Western Japan, the estimated number of treated people and population in each prefecture showed a linear association ( p < 0.001). Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Storr Liver Centre, Westmead Hospital, Westmead, New South Wales, Australia.
ORCID-Profile: Maito Suoh, Saeed Esmaili
Förderung
- Robert W. Storr Bequest to the Sydney Medical Foundation
- National Health and Medical Research Council of Australia
- Cancer Institute, NSW
Zitieren
APA
Suoh, M., Esmaili, S., Eslam, M., & George, J. (2026). Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. Journal of Viral Hepatitis, 33(8). https://doi.org/10.1111/jvh.70206
Vancouver
Suoh M, Esmaili S, Eslam M, George J. Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. Journal of Viral Hepatitis. 2026;33(8). doi:10.1111/jvh.70206
BibTeX
@article{Suoh2026,
author = {Suoh, Maito and Esmaili, Saeed and Eslam, Mohammed and George, Jacob},
title = {Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023},
journal = {Journal of Viral Hepatitis},
year = {2026},
volume = {33},
number = {8},
doi = {10.1111/jvh.70206}
}
EUVIMED